doesn't really make a big change for me..... I am here to wait for Phase 1 outcome.... not really bothered by daily movements.....if this drug has any potential (strong pre clinical)....this can easily be a multi bagger....
remember Novartis paid USD 9.8b for medicine company with an injectible PCSK9 for same cholesterol indication plus CV outcome data (still to be finalised, think they are doing P3)...
I am not comparing us with Medicine company as they were far ahead in their research and in biotech pre clinical data is too early.... but if we do end up having a strong P1, and given the company plan to licence it out post P1.... I think we are in for a killl.....
